A5044323050- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- DNA Repair Mechanisms
- Nuclear Structure and Function
- Retinal Diseases and Treatments
- RNA regulation and disease
- Lipoproteins and Cardiovascular Health
- Diabetes Management and Research
- Diet and metabolism studies
- Pancreatic function and diabetes
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Telomeres, Telomerase, and Senescence
- Chronic Kidney Disease and Diabetes
- Nutrition and Health in Aging
- Wound Healing and Treatments
- Atherosclerosis and Cardiovascular Diseases
- Cutaneous lymphoproliferative disorders research
- Health Promotion and Cardiovascular Prevention
- Retinal Imaging and Analysis
- Diabetes and associated disorders
- Cell Adhesion Molecules Research
- Pharmacology and Obesity Treatment
- Liver Disease Diagnosis and Treatment
- Lipid metabolism and disorders
- TGF-β signaling in diseases
Chiba University
2012-2025
Chiba University Hospital
2015-2024
International University of Health and Welfare
2019
Japanese Red Cross Narita Hospital
2019
Osaka University Hospital
2018
Clinical Research Management
2017
Duke Medical Center
2012-2017
Clinical Research Institute
2012-2017
University School
2015
Durham University
2012
Abstract Aims To compare the effects of ipragliflozin, a sodium‐dependent glucose transporter‐2 inhibitor, and those metformin on visceral fat area (VFA), prospective, multi‐centre, open‐label, blinded‐endpoint, randomized, controlled study was undertaken. The generated data were used to examine ipragliflozin indices hepatic steatosis liver fibrosis. Materials Methods In total, 103 Japanese patients with type‐2 diabetes (T2D), body mass index (BMI) ≥22 kg/m 2 glycated haemoglobin level...
CCN3 belongs to the CCN family, which constitutes multifunctional secreted proteins that act as matrix cellular regulators. We investigated pathophysiological roles of in vessels.We examined effects on proliferation and migration rat vascular smooth muscle cells (VSMC). knockout mice were created, phenotypes neointimal hyperplasia induced by photochemically thrombosis investigated. suppressed VSMC fetal bovine serum. The neutralizing antibody for transforming growth factor-beta did not...
<b><i>Background:</i></b> Although antidepressants are still a commonly used treatment for social anxiety disorder (SAD), significant proportion of patients fail to remit following antidepressants. However, no standard approach has been established managing such patients. This study aimed examine the effectiveness cognitive behavioral therapy (CBT) as an adjunct usual care (UC) compared with UC alone in SAD who remain symptomatic antidepressant treatment....
We assessed the effectiveness of sodium-glucose co-transporter 2 inhibitors (SGLT2is) in reducing administration frequency anti-vascular endothelial growth factor (VEGF) agents patients with diabetic macular oedema (DMO) using a health insurance claims database.
Abstract Aims Anti‐vascular endothelial growth factor (VEGF) therapy is the standard treatment for diabetic macular oedema (DMO); however, unmet needs remain. This study aimed to assess effectiveness of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in treating DMO. Materials and Methods multicentre randomised open‐label trial included 60 patients with DMO who were eligible anti‐VEGF therapy. Patients receive luseogliflozin or glimepiride. Ranibizumab was administered initially target...
A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study was conducted to evaluate the efficacy of treatment with ipragliflozin (sodium-dependent glucose transporter-2 inhibitor) versus metformin for visceral fat reduction and glycaemic control among Japanese patients type 2 diabetes treated sitagliptin, HbA1c levels 7%-10%, body mass index (BMI) ≥ 22 kg/m2 . Patients were randomly assigned (1:1) receive 50 mg or 1000-1500 daily. The primary outcome change in...
The incidence of type 2 diabetes is higher in elderly patients, whom this disease associated with dementia, falling, stroke and death. We utilized a continuous glucose monitoring device to analyze the relationship between hypoglycemia treatments identify risk factors for (defined as blood level <70 mg/dL).We classified 170 patients aged ≥65 years who were receiving steady-state medication (29 inpatients) into hypoglycemic non-hypoglycemic groups, compared their glycosylated hemoglobin...
Purpose: To determine the efficacy of systemic sodium-glucose co-transporter 2 inhibitors (SGLT2i) on diabetic macular edema (DME). Methods: The medical records patients with DME a central retinal thickness (CRT) ≥320 µm in men and 305 women, more than 6 months after initiation diabetes mellitus treatment, were reviewed. CRT best-corrected visual acuity (BCVA) evaluated before SGLT2i non-SGLT2i treatments. Results: There 24 eyes 19 that treatment naïve or had not received treatments for...
Patients with type 2 diabetes are at high risk for cardiovascular disease. Although hydroxymethylglutaryl-CoA reductase inhibitors (statins) can reduce events, residual remains even after target low-density lipoprotein cholesterol (LDL-C) levels have been achieved. Lipoprotein particle size and fraction changes thought to contribute such risks. The purpose of this study was evaluate the effects n-3 polyunsaturated fatty acids (n-3 PUFAs), predominantly eicosapentaenoic acid docosahexaenoic...
Patients with Werner syndrome present diverse signs of aging that begin in adolescence. A Japanese nationwide survey was conducted to establish a registry could clarify the disease profile patients syndrome. The questionnaires were sent 7888 doctors. identified 116 diagnosed based on diagnosis criteria. Forty enrolled registry. Data clinical symptoms, treatment information, and laboratory examination from who provided informed consent collected. data at enrollment analyzed. patients' average...
To compare the effects of ipragliflozin, a sodium-glucose transporter 2 inhibitor, with those metformin on visceral fat (as well as muscles and bones) in Japanese elderly patients type diabetes (T2D), we conducted sub-analysis prospective, multicenter, blinded-endpoint randomized-controlled study. In total, 103 T2D (body mass index ≥ 22 kg/m2; glycated hemoglobin, 7–10%) being treated sitagliptin (a dipeptidyl peptidase-4 inhibitor) were included randomized to receive ipragliflozin or...
Background:The pharmacodynamic effects of changing from standard-dose clopidogrel to low-dose (3.75 mg) prasugrel in Japanese patients are largely unknown.Methods and Results:A total 53 consecutive with stable coronary artery disease (CAD) who received aspirin were enrolled. Clopidogrel was switched 3.75 mg prasugrel. At day 14, 75 clopidogrel. Platelet reactivity measured using the VerifyNow assay at baseline, 28. P2Y12 reaction units (PRU) >208 defined as high on-treatment platelet (HPR)....
Recent randomized clinical trials have suggested that sodium-glucose cotransporter 2 inhibitors might reduce cardiovascular events and heart failure, renal protective effects. Despite these remarkable benefits, the effects of on bone muscle are unclear.
The effects of the sodium-dependent glucose transporter-2 inhibitor ipragliflozin were compared with metformin in a previous study, which revealed that reduced visceral fat content by 12%; however, underlying mechanism was unclear. Therefore, this sub-analysis aimed to compare metabolomic changes associated and may contribute their biological effects.A randomized controlled study.Chiba University Hospital ten hospitals Japan.Fifteen patients type 2 diabetes group 15 matching characteristics,...
Abstract Podocalyxin is a cell surface sialomucin, which expressed in not only glomerular podocytes but also vascular endothelial cells. Urinary podocalyxin used as marker for disease. However, there are no reports describing serum (s-Podxl) levels. Therefore, the association between s-Podxl levels and clinical parameters were examined with 52 patients. level was evaluated using enzyme-linked immunosorbent assay. The median 14.2 ng/dL (interquartile range: 10.8–22.2 ng/dL). There significant...
Diabetic macular edema (DME) is a vision-threatening condition that develops in diabetic patients. The first-line therapy for DME intravitreal injections of antivascular endothelial growth factor (anti-VEGF) agents; however, the high frequency repeat injections, invasiveness procedure, and cost are drawbacks this treatment. purpose report to present our findings 3 patients with chronic whose was resolved soon after oral doses sodium-glucose cotransporter-2 (SGLT2) inhibitors were used. Case...